Driving Factors and Scale Effects of Residents' Willingness to Pay for Environmental Protection under the Impact of COVID-19

In recent years, environmental degradation and the COVID-19 pandemic have seriously affected economic development and social stability. Addressing the impact of major public health events on residents' willingness to pay for environmental protection (WTPEP) and analyzing the drivers are necessary for improving human well-being and environmental sustainability. We designed a questionnaire to analyze the change in residents' WTPEP before and during COVID-19 and an established ordinary least squares (OLS), spatial lag model (SLM), spatial error model (SEM), geographically weighted regression (GWR), and multiscale GWR to explore driver factors and scale effects of WTPEP based on the theory of environment Kuznets curve (EKC). The results show that (1) WTPEP is 0–20,000 yuan before COVID-19 and 0–50,000 yuan during COVID-19. Residents' WTPEP improved during COVID-19, which indicates that residents' demand for an ecological environment is increasing;(2) The shapes and inflection points of the relationships between income and WTPEP are spatially heterogeneous before and during COVID-19, but the northern WTPEP is larger than southern, which indicates that there is a spatial imbalance in WTPEP;(3) Environmental degradation, health, environmental quality, and education are WTPEP's significant macro-drivers, whereas income, age, and gender are significant micro-drivers. Those factors can help policymakers better understand which factors are more suitable for macro or micro environmental policy-making and what targeted measures could be taken to solve the contradiction between the growing ecological environment demand of residents and the spatial imbalance of WTPEP in the future.

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Objective: To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19). Design: Multicentre, open label, randomised controlled trial. Setting 16 government designated covid-19 treatment centres in China, 11 to 29 February 2020. Participants: 150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone). Interventions Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively). Main outcome measure: Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.